Drug Patents owned by Santen

1. List of Omlonti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648097 SANTEN Pyridylaminoacetic acid compound
Oct, 2029

(6 years from now)

US10774072 SANTEN Crystal of N-substituted sulfonamide compound
Jun, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 SANTEN Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(6 years from now)

US10765750 SANTEN Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10179127 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US11197849 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US10702511 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

US9415038 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

USRE48183 SANTEN Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

2. List of Verkazia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524779 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US9956289 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US9220694 SANTEN Emulsion compositions containing cetalkonium chloride
Jan, 2026

(2 years from now)

US7973081 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US8298568 SANTEN Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Nov, 2027

(4 years from now)

US9132071 SANTEN Compositions containing quaternary ammonium compounds
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 23, 2028
New Product (NP) Jun 23, 2023

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 June, 2021

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic